Alkem Laboratories has informed that the Board of Directors at its meeting held today i.e., 07th November, 2023, has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2023; approved the amendment to object clause of the Memorandum of Association of the Company by inserting certain new object clauses after sub clause 2 of Clause III(A) - Main Objects ('The objects to be pursued by the Company on its incorporation'), subject to approval of shareholders of the Company through Postal Ballot. Accordingly, it is enclosing Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed. The meeting of the Board of Directors of the Company commenced at 11.00 am and concluded at 1.40 pm.
The above information is a part of company’s filings submitted to BSE.
